Asset Allocation

As of March 31, 2026.
Type % Net
Cash 26.48%
Stock 69.60%
Bond 5.34%
Convertible 0.00%
Preferred 0.00%
Other -1.42%
View Asset Allocation
Start Trial

Market Capitalization

As of March 31, 2026
Large 86.78%
Mid 9.62%
Small 3.59%
View Market Capitalization
Start Trial

Region Exposure

% Developed Markets: 74.66%    % Emerging Markets: 0.01%    % Unidentified Markets: 25.32%

Americas 49.73%
49.64%
Canada 0.01%
United States 49.63%
0.08%
Colombia 0.00%
As of March 31, 2026. Region breakdown data is calculated by using the long position holdings of the portfolio.
Greater Europe 4.91%
United Kingdom 0.04%
0.23%
Belgium 0.00%
Finland 0.00%
France 0.00%
Germany 0.00%
Ireland 0.12%
Italy 0.00%
Netherlands 0.04%
Norway 0.00%
Sweden 0.00%
Switzerland 0.07%
0.00%
4.64%
Israel 4.63%
United Arab Emirates 0.00%
Greater Asia 20.04%
Japan 0.05%
0.02%
Australia 0.02%
19.96%
Hong Kong 1.23%
Singapore 0.00%
South Korea 0.01%
Taiwan 18.71%
0.01%
China 0.01%
Unidentified Region 25.32%

Bond Credit Quality Exposure

AAA --
AA --
A --
BBB --
BB --
B --
Below B --
    CCC --
    CC --
    C --
    DDD --
    DD --
    D --
Not Rated --
Not Available --
Short Term --
No Data Available
View Bond Credit Quality Exposure
Start Trial

Stock Sector Exposure

Cyclical
20.98%
Materials
0.16%
Consumer Discretionary
10.31%
Financials
9.99%
Real Estate
0.51%
Sensitive
58.58%
Communication Services
1.43%
Energy
1.63%
Industrials
4.15%
Information Technology
51.36%
Defensive
11.35%
Consumer Staples
0.11%
Health Care
11.15%
Utilities
0.10%
Not Classified
0.02%
Non Classified Equity
0.02%
As of March 31, 2026
View Region Exposure
Start Trial

Bond Sector Exposure

As of March 31, 2026
Type % Net
Government 99.87%
Corporate 0.12%
Securitized 0.00%
Municipal 0.01%
Other 0.00%
View Bond Sector Exposure
Start Trial

Bond Maturity Exposure

Short Term --
Less than 1 Year --
Intermediate --
1 to 3 Years --
3 to 5 Years --
5 to 10 Years --
Long Term --
10 to 20 Years --
20 to 30 Years --
Over 30 Years --
Other --
No Data Available
View Bond Maturity Exposure
Start Trial